-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the weekly report of the National Influenza Center, sentinel hospitals in the north and south reported 212% and 325% of influenza-like case visits compared to the same period last year1
.
The reason for the recent fever is not simply infection with the new crown, but also many are influenza and even double infection
.
Early initiation of antiviral therapy is critical
for infected patients during this special period.
It is necessary to fully consider the antiviral spectrum of drugs and cover influenza viruses and new coronaviruses
as much as possible.
This winter, the risk of influenza and new crown epidemics is high
.
How will dual infection affect patients? Are there any drugs that are effective for both influenza and coronavirus?
Faveravir: small molecule, dual-mechanism broad-spectrum antiviral
Shenzhen study - faviravir against new coronavirus, the efficacy is precise and safe
epilogue
END
.
The reason for the recent fever is not simply infection with the new crown, but also many are influenza and even double infection
.
Early initiation of antiviral therapy is critical
for infected patients during this special period.
It is necessary to fully consider the antiviral spectrum of drugs and cover influenza viruses and new coronaviruses
as much as possible.
This winter, the risk of influenza and new crown epidemics is high
.
How will dual infection affect patients? Are there any drugs that are effective for both influenza and coronavirus?
Faveravir: small molecule, dual-mechanism broad-spectrum antiviral
• In fact, in the early stages of new coronavirus infection, the use of antiviral drugs during the rapid replication phase of the virus is the key to the treatment of new coronavirus infection "to the
cause".
Of all antiviral drugs, small molecule drugs have more advantages
.
First of all, small molecule drugs have relatively conservative targets, which can act on intracellular and extracellular targets, with almost no immunogenicity, and secondly, most small molecule drugs are convenient to administer and are conducive to the treatment
of mild patients.
At the same time, small molecule drugs have relatively low sensitivity to the storage environment and are convenient
for storage and transportation.
The anti-coronavirus targets currently on the market or under development are mainly Mpro and RdRp2
.
•Faviravir is a novel RNA-dependent broad-spectrum antiviral drug with a class of RNA polymerase (RdRp) inhibitors that exerts antiviral effects
by inhibiting viral RNA replication and inducing deadly mutations in viruses.
Shenzhen study - faviravir against new coronavirus, the efficacy is precise and safe
Faveravir was the first drug approved for potential efficacy against the novel coronavirus in China during the epidemic, and has been approved as an antiviral drug for the treatment of new or re-circulating influenza in adults, and a study conducted in the Third People's Hospital of Shenzhen also observed that faveravir can be effective in the treatment of novel coronavirus infection3
.
Research protocol
An open-label, non-randomized, controlled before-and-after study of patients with nasopharyngeal swab samples tested positive for novel coronavirus RNA with less than 7 days from onset to enrollment
.
Efficacy
to treatment was assessed by the time to viral clearance and CT improvement rate in patients at day 14 post-treatment.
Study results
➢ Faviravir group significantly shortened the viral nucleic acid conversion time
compared with lopinavir/ritonavir.
The median time to viral clearance in patients treated with faveravir was 4 days, significantly shorter than that of the control group by 7 days (P < 0.
001).
➢Faviravir for 14 days significantly improved chest imaging findings compared with lopinavir/ritonavir
.
After 14 days of treatment, the rate of chest imaging improvement in the faviravir group was significantly higher than that in the control group (91.
43% vs 62.
22%, p=0.
004).
➢ Faviravir treatment for 14 days had a significantly lower
rate of adverse events than lopinavir/ritonavir.
After 14 days of treatment, the incidence of adverse events in the faviravir group was significantly lower than in the control group (11.
43% vs 55.
56%, p<0.
001).
epilogue
In 2023, we officially began to live with
the coronavirus.
However, in this season of high incidence of influenza and new crown, it is particularly important
to choose a suitable antiviral drug to start antiviral treatment as soon as possible.
At present, China has approved faviravir for the treatment of new viral infections, and a number of clinical evidence has continuously confirmed that the treatment of COVID-19 by faviravir can quickly improve the symptoms of patients, shorten the time for the virus to turn negative, and has good safety, which can solve the current problem of shortage of antiviral drugs for you, and look forward to becoming your good clinical assistant
.
END
References
1.
Weekly Influenza Surveillance Week 52, 2022.
2.
Zhong L, et al.
Precis Clin Med.
2022 Sep 24; 5(4) pbac024.
3.
Cai Q, et al.
Engineering (Beijing).
2020 Oct; 6(10):1192-1198.
